New depression drug shows promise in early trial

NCT ID NCT06400121

Recruiting now Symptom relief Sponsor: Rebecca Price Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tests a single injection of apimostinel, a fast-acting antidepressant, in 150 adults with major depression. Half also receive digital cognitive training sessions to see if it extends the drug's effects. The trial is placebo-controlled and double-blind, meaning neither participants nor researchers know who gets the real drug. The goal is to quickly ease depression symptoms with minimal side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apimostinel
What this could lead to: If successful, this could provide a new, fast-acting antidepressant option with fewer side effects, and show that digital cognitive training can make the benefits last longer.
What could go wrong: This is an early Phase 2 trial with only 150 people. The drug may not work better than placebo, and the cognitive training may not extend effects. Side effects are reported as minimal, but long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION

Contacts and locations

Locations

Western Psychiatric Institute and Clinic
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.